Endocrine Abstracts

A 6-hour octreotide suppression test (OST) is useful in the selection of patients with acromegaly for chronic somatostatin depot analogues treatment. However, it is time consuming and that brings inconvenience to patients. We aim to simplify the blood sampling of OST, and determine the reliability of a short version of the classic 6-hour OST. The data provided in the supplementary tables of the primary manuscript were used to re-analyze the efficacies of the simplified OST tes...

Objective: The distinction between constitutional delay of growth and puberty (CDGP) and congenital hypogonadotropic hypogonadism (CHH) in males with delayed puberty is difficult but important for timely treatment. We aimed to summarize the sensitivity and specificity of serum inhibin B (INHB) level in distinguishing CHH with CDGPin boys.Methods: Studies in the PubMed, EMBASE and Cochrane Library databases were systematically searched from the date of da...

Context: Postoperative central diabetes insipidus (PDI) is one of the most common complications of surgical treatment of pituitary adenoma, temporary or permanant. The diagnosis of PDI was suspicious in some occasions and inappropriate prescription of antidiuretic hormone was harmful. Generally, high level serum uric acid (HUA) was a clue for central diabetes insipidus, but we did not know its role for the brain postoperative subjects. As we know, the food intake and health co...

Introduction: Osilodrostat (oral 11β-hydroxylase inhibitor) demonstrated rapid, sustained cortisol normalisation in Phase III studies (LINC 3, NCT02180217; LINC 4, NCT02697734) in patients with Cushing’s disease (CD). Relative osilodrostat bioavailability is ~20% higher in Asian patients than other ethnicities; body weight is not a major determinant of this difference. This analysis of LINC 3 and LINC 4 evaluated osilodrostat efficacy and safety in Asian and non-Asia...

IntroductionOsilodrostat, a potent, oral 11β-hydroxylase inhibitor, normalized mean urinary free cortisol (mUFC) in most patients with CD during a Phase III, randomized-withdrawal study. We now report findings from a Phase III study of osilodrostat in patients with CD that featured an initial double-blind, randomized, placebo-controlled period (LINC 4; NCT02697734).MethodsAdults with CD (mUFC > 1.3 &...